Can primaquine therapy for vivax malaria be improved?

Baird, JK and Rieckmann, KH (2003) Can primaquine therapy for vivax malaria be improved?. Trends In Parasitology, 19 3: 115-120. doi:10.1016/S1471-4922(03)00005-9

Author Baird, JK
Rieckmann, KH
Title Can primaquine therapy for vivax malaria be improved?
Journal name Trends In Parasitology   Check publisher's open access policy
ISSN 1471-4922
Publication date 2003
Sub-type Article (original research)
DOI 10.1016/S1471-4922(03)00005-9
Volume 19
Issue 3
Start page 115
End page 120
Total pages 6
Editor S. Hirst
L. Stapley
Place of publication United Kingdom
Publisher Elsevier Ltd, Trends Journals
Collection year 2003
Language eng
Subject C1
321202 Epidemiology
730212 Disease distribution and transmission
Abstract The incidence and range of endemic malaria caused by Plasmodium vivax has expanded during the past 30 years. This parasite forms hypnozoites in the liver, creating a persistent reservoir of infection. Primaquine (PQ), introduced 50 years ago, is the only drug available to eliminate hypnozoites. However, lengthy treatment courses and follow-up periods are not conducive to assessing the effectiveness of this drug in preventing relapses. Resistance to standard therapy could be widespread. Studies are urgently needed to gauge this problem and to determine the safety, tolerability and efficacy of shorter courses and higher doses of PQ.
Keyword Parasitology
Resistant Plasmodium-vivax
Placebo-controlled Trial
Q-Index Code C1

Document type: Journal Article
Sub-type: Article (original research)
Collections: 2004 Higher Education Research Data Collection
Centre for Military and Veterans' Health Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 86 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 99 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Wed, 15 Aug 2007, 02:55:05 EST